Expression of the PLS3 Gene in Circulating Cells in Patients with Colorectal Cancer
Languages of publication
Circulating tumor cells (CTC) are cells in circulating blood that have the antigen and gene features of tumor cells of a specific type. Since they can be potentially used in diagnostics and monitoring of treatment of many tumors, they have been attracting attention of researchers worldwide. Plastin-3 (PL S3) is one of such markers of CTC. The aim of the study was to assess expression of PL S3 in CTC in patients with colorectal cancer, to conduct a statistical analysis and to demonstrate a link between expression of PL S3 and progress of the disease, level of CEA and Ca19-9 markers, gender and age of the patients. Material and methods. A group of 85 patients of the Department of General and Colorectal Surgery of the Medical University in Łódź were enrolled in this study. Circulating tumor cells were isolated from whole blood of patients with colorectal cancer and an analysis of PL S3 gene expression in CTC was conducted. The next step was to conduct a statistical analysis and to demonstrate a link between expression of PL S3 in patients’ CTC and progress of the disease, level of CEA and Ca19-9 markers, gender and age of the patients. Results. PL S3 is a marker which can be potentially used in prediction and monitoring of colorectal cancer. A link between expression of PL S3 in CTC of patients with colorectal cancer and metastasis to lymph nodes has been demonstrated. It may be of key importance how PL S3 could impact the qualification to supplementary cancer treatment in patients with stage II colorectal cancer. A link between expression of PL S3 gene in CTC and gender requires further in-depth studies. It is beyond doubt that PL S3 must be further investigated to determine its role in diagnostics, prediction, treatment and monitoring of treatment of colorectal cancer
1 - 2 - 2015
3 - 7 - 2015
- 1. Vona G, Sabile A, Louha M et al.: Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000; 156: 57-63.
- 2. Hugo H, Ackland ML, Blick T et al.: Epithelial- mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007; 213: 374-38.
- 3. Paterlini-Brechot P, Benali NL : Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007; 253: 180-204.
- 4. Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003; 3: 55-63.
- 5. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54.
- 6. Gurtowska N, Bajek A, Olkowska J et al.: Identification of circulating tumor cells as a promising method of genitourinary cancer diagnosis. Postepy Hig Med Dosw (Online). 2012; 66: 983-90.
- 7. World Cancer Research Fund and American Institute for Cancer Research Food. Nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, (DC): American Institute for Cancer Research; 2007.
- 8. Bamias A, Basdanis G, Xanthakis I et al.: Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy or hemoradiotherapy: a pooled analysis of two randomized studies. Int J Gastrointest Cancer 2005; 36: 29-38.
- 9. Compton C, Fenoglio-Preiser CM, Pettigrew N et al.: American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88: 1739-57.
- 10. Bustin SA, Gyselman VG, Williams NS et al.: Detection of cytokeratins 19/20 and guanylyl cyclase in peripheral blood of colorectal cancer patients. Br J Cancer 1999; 79: 1813-20.
- 11. Burchill SA, Bradbury MF, Pittman K et al.: Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction. Br J Cancer 1995; 71:278-81.
- 12. Kamiyama H, Noda H, Konishi F et al.: Molecular biomarkers for the detection of metastatic colorectal cancer cells. World J Gastroenterol 2014; 20(27): 8928-38.
- 13. Pantel K, Brakenhoff RH, Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8: 329-40.
- 14. Sleijfer S, Gratama JW, Sieuwerts AM et al.: Circulating tumour cell detection on its way to routine diagnostic implementation? Eur J Cancer 2007; 43: 2645-50.
- 15. Sastre J, Maestro ML, Puente J et al.: Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008; 19: 935-38.
- 16. Riethdorf S, Fritsche H, Muller V et al.: Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007; 13: 920-28.
- 17. Lacroix M: Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 2006; 13: 1033-67
- 18. Kaiser J: Medicine. Cancer’s circulation problem. Science 2010; 327: 1072-74.
- 19. Yokobori T, Iinuma H, Shimamura T et al.: Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 2013; 73(7): 2059-69.
- 20. Ning Y, Gerger A, Zhang W et al.: Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. Mol Cancer Ther 2014; 13(2): 528-39.
- 21. Szkandera J, Winder T, Stotz M et al.: A common gene variant in PLS3 predicts colon cancer recurrence in women. Tumour Biol 2013: 34(4): 2183-88.
- 22. Sugimachi K, Yokobori T, Iinuma H et al.: Aberrant expression of plastin-3 via copy number gain induces the epithelial-mesenchymal transition in circulating colorectal cancer cells. Ann Surg Oncol 2014: 21(11): 3680-90.
Publication order reference